CFG
REGN icon

Cooper Financial Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Cooper Financial Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$433K Sell
695
-263
-27% -$179K 0.04% 285
2026
Q1 		$740K Sell
958
-35
-4% -$26.8K 0.07% 198
2025
Q4 		$766K Sell
993
-47
-5% -$31.9K 0.08% 178
2025
Q3 		$585K Sell
1,040
-87
-8% -$49.2K 0.06% 217
2025
Q2 		$591K Buy
1,127
+369
+49% +$206K 0.07% 219
2025
Q1 		$480K Buy
758
+225
+42% +$155K 0.06% 243
2024
Q4 		$380K Sell
533
-66
-11% -$55.4K 0.05% 269
2024
Q3 		$630K Buy
599
+320
+115% +$356K 0.08% 207
2024
Q2 		$293K Buy
+279
New +$270K 0.04% 304
2022
Q2 		– Sell
-553
Closed -$386K – 279
2022
Q1 		$386K Buy
+553
New +$350K 0.15% 138

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Cooper Financial Group's REGN Position: Q2 2026 in Review

Cooper Financial Group reduced its Regeneron Pharmaceuticals (REGN) stake by 27% in Q2 2026, selling an estimated $179K and leaving 695 shares worth $433K. The position accounts for 0.04% of the portfolio, ranked #285.

Cooper Financial Group first reported a position in REGN in Q1 2022 and has held it in 10 quarters since. The position peaked at $766K in Q4 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Cooper Financial Group held 695 shares of Regeneron Pharmaceuticals worth $433K as of Q2 2026.
  • Cooper Financial Group sold 263 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $179K.
  • Regeneron Pharmaceuticals made up 0.04% of Cooper Financial Group's portfolio in Q2 2026, its #285 holding.
  • Cooper Financial Group first reported a position in Regeneron Pharmaceuticals in Q1 2022 and has held it in 10 quarters since.
  • Cooper Financial Group's Regeneron Pharmaceuticals position peaked at $766K in Q4 2025.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Cooper Financial Group's 13F filing for Q2 2026, filed 8 Jul 2026.